KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Invested Capital (2018 - 2025)

Vir Biotechnology's Invested Capital history spans 8 years, with the latest figure at $765.3 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 34.39% year-over-year to $765.3 million; the TTM value through Dec 2025 reached $765.3 million, down 34.39%, while the annual FY2025 figure was $765.3 million, 34.39% down from the prior year.
  • Invested Capital for Q4 2025 was $765.3 million at Vir Biotechnology, down from $796.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $2.1 billion in Q3 2022 and bottomed at $675.4 million in Q1 2021.
  • The 5-year median for Invested Capital is $1.4 billion (2021), against an average of $1.4 billion.
  • The largest annual shift saw Invested Capital surged 196.29% in 2022 before it tumbled 35.84% in 2025.
  • A 5-year view of Invested Capital shows it stood at $1.4 billion in 2021, then soared by 45.12% to $2.1 billion in 2022, then fell by 23.47% to $1.6 billion in 2023, then decreased by 26.65% to $1.2 billion in 2024, then tumbled by 34.39% to $765.3 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Invested Capital are $765.3 million (Q4 2025), $796.1 million (Q3 2025), and $947.5 million (Q2 2025).